The present invention relates to in vivo imaging and in particular to magnetic resonance imaging (MRI). Provided by the present invention is a pharmaceutical formulation suitable for use in an MRI procedure and which offers advantages over known such formulations. A particular dose of the pharmaceutical formulation of the invention is also envisioned as well as the use of said dose in a method of in vivo imaging. This present invention provides for simultaneous administration of a liver specific agent and a second MR contrast agent that is capable of better/further enhancing the dynamic vascular phase in a patient. The method of the invention has the advantage of simplicity and patient comfort, compared to sequential injections. Furthermore, the method of the invention provides the advantage that it can enable a lower cumulative dose of contrast agents.

The present invention relates to an imaging diagnostic method, comprising a contrast agent including a contrast enhancer in a magnetic resonance imaging (MRI) assisted diagnosis of carcinoma diseases or carcinomas, in particular of hepatocellular carcinoma (HCC). The contrast agent is preferably a gadolinium compound, preferably Gd-DTPA including iRGD as a contrast enhancer, for the improved imaging of carcinomas, in particular HCC, in MRI. The invention furthermore relates to a method for the risk stratification of patients and subjects using the aforementioned diagnosis.

Disclosed herein are complexes of gadolinium metal, ligand and meglumine that are substantially free of non-aqueous solvents. In particular, solvent-free complexes of 1) gadopentetate dimeglumine and 2) gadoterate meglumine are disclosed and methods of their preparation are disclosed. In addition, methods are disclosed for purifying reactants, monitoring and controlling pH, quantifying the free gadolinium content, quantifying the concentration of gadolinium-ligand complex in aqueous solution, and procedures for producing a drug product in one step. The one step process eliminates the need to dry the gadolinium-ligand complex, which is typically highly hygroscopic. The one step process includes purification steps that do not require the use of non-aqueous solvents.

The present disclosure is concerned with the technical field of generation of artificial contrast-enhanced radiological images.

The present disclosure relates to the technical field of generation of synthetic images, in particular synthetic medical images. The subjects of the present disclosure are a method, a computer system and a computer-readable storage medium comprising a computer program for detecting artifacts in synthetic images, in particular synthetic medical images.

The invention provides systems and methods for providing a diagnostic examination to a patient, including, but not limited to a determination of the permeability of a patients' body cavity.

The present invention relates to the use of a combination of several contrast agents having different properties with respect to imaging representation.

Methods are provided for measuring the activity of TMEM sites in a tumor comprising measuring a transient increase in permeability of blood vessels at TMEM sites that allows tumor cells to enter the blood vessels, wherein permeability is measured using a modality selected from the group consisting of MRI, PET, CT, and SPECT, and wherein a transient increase in permeability indicates that a TMEM site is active. The method can include, for example, obtaining a MenaINV score assessed by fine needle aspiration in the same tissue. The present invention can be used as both a prognostic for dissemination and a predictive end point for identification and validation of dissemination inhibitors/anti-metastasis drugs.

Unmodified graphene oxide conjugated with hydrophilic small molecules for cellular delivery.

The disclosure relates to methods of (i) treating a subject for a liver fibrotic disease, in particular, primary sclerosing cholangitis or (ii) modulating .sub.V.sub.6 integrin, .sub.V.sub.1 integrin, or both .sub.V.sub.6 integrin and .sub.V.sub.1 integrin in a subject in need thereof, comprising administration of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4- ylamino)butanoic acid, or a pharmaceutically acceptable salt thereof as described herein. Optionally, a second drug, such as ursodeoxycholic acid or a pharmaceutically acceptable salt thereof, can be co-administered. The compounds and pharmaceutical compositions thereof are .sub.V.sub.6 integrin inhibitors that are useful for treating fibrosis such as primary sclerosing cholangitis.